The Claim
Oral administration of biliverdin (20 mg/kg daily for 2 weeks) reduces adipocyte size and improves insulin resistance in obese mice fed a high-fat diet, accompanied by decreased expression of TNF-α and Cd11c in adipose tissue.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In obese mice on a high-fat diet, daily oral biliverdin for two weeks reduces fat cell size and improves insulin resistance, while lowering levels of the inflammatory markers TNF-α and Cd11c in fat tissue.
See the scientific wording
In obese mice fed a high-fat diet, oral administration of biliverdin (20 mg/kg daily for 2 weeks) reduces adipocyte size and improves insulin resistance, associated with decreased expression of the proinflammatory cytokine TNF-α and M1 macrophage marker Cd11c in adipose tissue.
When biliverdin is taken by mouth, it turns into bilirubin inside the body. Bilirubin blocks the production of harmful reactive molecules in fat tissue, which reduces inflammation. This causes fat cells to shrink and stops immune cells from releasing signals that block insulin. As a result, the body uses insulin better and blood sugar levels improve.
What the research says
1 studyStudy: Bilirubin reduces visceral obesity and insulin resistance by suppression of inflammatory cytokines
In obese mice fed a fatty diet, giving them biliverdin made their fat cells smaller, helped their bodies use insulin better, and reduced inflammation in fat tissue — just like the claim said.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.